Literature DB >> 30470396

Epidemiology and Molecular Epidemiology.

Luc Bauchet1, Quinn T Ostrom2.   

Abstract

Incidence, prevalence, and survival for diffuse low-grade gliomas and diffuse anaplastic gliomas (including grade II and grade III astrocytomas and oligodendrogliomas) varies by histologic type, age at diagnosis, sex, and race/ethnicity. Significant progress has been made in identifying potential risk factors for glioma, although more research is warranted. The strongest risk factors that have been identified thus far include allergies/atopic disease, ionizing radiation, and heritable genetic factors. Further analysis of large, multicenter epidemiologic studies, and well-annotated "omic" datasets, can potentially lead to further understanding of the relationship between gene and environment in the process of brain tumor development.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffuse glioma; Epidemiology; Incidence; Low-grade glioma; Population-based; Survival

Mesh:

Year:  2019        PMID: 30470396     DOI: 10.1016/j.nec.2018.08.010

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  9 in total

1.  Fast intraoperative histology-based diagnosis of gliomas with third harmonic generation microscopy and deep learning.

Authors:  Max Blokker; Philip C de Witt Hamer; Pieter Wesseling; Marie Louise Groot; Mitko Veta
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

Review 2.  Therapeutic Options in Neuro-Oncology.

Authors:  Mariana Afonso; Maria Alexandra Brito
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

3.  Elevated Serum Lactate in Glioma Patients: Associated Factors.

Authors:  Beathe Sitter; Annamaria Forsmark; Ole Solheim
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

4.  Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study.

Authors:  Li Yao; Linghui Zhou; Yujiao Deng; Yi Zheng; Pengtao Yang; Meng Wang; Shanshan Dong; Qian Hao; Peng Xu; Na Li; Ying Wu; Zhen Zhai; Lijuan Lyu; Zhijun Dai
Journal:  Onco Targets Ther       Date:  2019-10-07       Impact factor: 4.147

5.  In Vivo Biodistribution of Engineered Lipid Microbubbles in Rodents.

Authors:  Letizia Oddo; Gaio Paradossi; Barbara Cerroni; Carmit Ben-Harush; Eti Ariel; Francesco Di Meco; Zvi Ram; Rachel Grossman
Journal:  ACS Omega       Date:  2019-08-08

6.  lncRNA TPTEP1 inhibits stemness and radioresistance of glioma through miR‑106a‑5p‑mediated P38 MAPK signaling.

Authors:  Ting Tang; Ling-Xing Wang; Mei-Li Yang; Rong-Mou Zhang
Journal:  Mol Med Rep       Date:  2020-09-28       Impact factor: 2.952

7.  Sex Differences in Time to Treat and Outcomes for Gliomas.

Authors:  Nickolas Stabellini; Halle Krebs; Nirav Patil; Kristin Waite; Jill S Barnholtz-Sloan
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

Review 8.  Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.

Authors:  Shalini Sundramurthi Chelliah; Ervin Ashley Lourdes Paul; Muhamad Noor Alfarizal Kamarudin; Ishwar Parhar
Journal:  Molecules       Date:  2021-02-22       Impact factor: 4.411

9.  Associations of lncRNA H19 Polymorphisms at MicroRNA Binding Sites with Glioma Susceptibility and Prognosis.

Authors:  Yujiao Deng; Linghui Zhou; Jia Yao; Yu Liu; Yi Zheng; Si Yang; Ying Wu; Na Li; Peng Xu; Lijuan Lyu; Dai Zhang; Jun Lyu; Zhijun Dai
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-13       Impact factor: 8.886

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.